Lung Adenocarcinoma during Pregnancy: 11-Year Follow-Up.
ALK inhibitors
Adenocarcinoma
Cancer and pregnancy
Lung cancer
Radiation therapy
Radiosurgery
Targeted therapy
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
01
05
2020
accepted:
03
05
2020
entrez:
5
9
2020
pubmed:
5
9
2020
medline:
5
9
2020
Statut:
epublish
Résumé
The incidence of lung cancer during pregnancy is rising due to the high rate of smokers in young women and the late mean age of pregnancy; in addition, considering that the patients are young women with a higher incidence of molecular alterations, molecular testing in lung adenocarcinoma should always be performed, even in pregnancy. Here, we report the case of a lung adenocarcinoma diagnosed during pregnancy with a long survival who benefitted from brain radiotherapy, conventional chemotherapy, and ALK TKI-targeted treatment. It reveals the safety of whole brain radiotherapy during pregnancy and consideration of other brain radiation techniques even in palliative cases, which should be personalized and managed by a multidisciplinary team. However, upfront management of brain metastasis in ALK-positive patients remains unresolved.
Identifiants
pubmed: 32884536
doi: 10.1159/000508360
pii: cro-0013-0892
pmc: PMC7443663
doi:
Types de publication
Case Reports
Langues
eng
Pagination
892-895Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Ann Oncol. 2013 Oct;24 Suppl 6:vi160-70
pubmed: 23813932
Ann Oncol. 2016 Sep;27(suppl 5):v1-v27
pubmed: 27664245
Future Oncol. 2019 Aug;15(24):2841-2855
pubmed: 31364872
Lung Cancer. 2018 Jul;121:37-40
pubmed: 29858024
J Clin Oncol. 2009 Jan 1;27(1):45-51
pubmed: 19029418